









Markets
/
Stocks
/
nasdaq-plrz
/

Polyrizon Ltd

PLRZ

0.983USD

-0.007-0.75%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

5.78MMarket Cap

--P/E TTM



Polyrizon Ltd

0.983

-0.007-0.75%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Polyrizon Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Polyrizon Ltd's Score

Industry at a Glance

Industry Ranking

299 / 501

Overall Ranking

564 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Polyrizon Ltd Highlights

StrengthsRisks

Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -2.14, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 370.57K shares, increasing 49.99% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Polyrizon Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.60, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -2.14, which is -99.70% below the recent high of -0.01 and -505.10% above the recent low of -12.92.

Score

Industry at a Glance

Previous score

6.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 299/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.04.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 6.44, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 1.23 and the support level at 1.00, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.37

Change

0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.030

Sell

RSI(14)

39.281

Neutral

STOCH(KDJ)(9,3,3)

15.296

Oversold

ATR(14)

0.055

Low Volatility

CCI(14)

-140.160

Sell

Williams %R

89.364

Oversold

TRIX(12,20)

-0.290

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.011

Sell

MA10

1.044

Sell

MA20

1.095

Sell

MA50

1.082

Sell

MA100

1.038

Sell

MA200

0.867

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Sabby Management, LLC

340.46K

UBS Financial Services, Inc.

29.59K

+82102.78%

Citi Investment Research (US)

507.00

Srugo (Raul)

124.00

-12.06%

Srugo (Itzhak)

119.00

-15.60%

Srugo (Yoav)

117.00

-17.02%

Srugo (Sofi Yochelman)

115.00

Independent Financial Partners

100.00

L.I.A. Pure Capital Ltd

60.00

-39.39%

Izraeli (Tomer)

47.00

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.